Lebrikizumab - Roche

Drug Profile

Lebrikizumab - Roche

Alternative Names: MILR1444A; MILR1444Ab; RG-3637; RO-5490255; TNX-650

Latest Information Update: 05 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tanox
  • Developer Chugai Pharmaceutical; Comprehensive Clinical Research Network; Dermira; Genentech; Roche; Tanox
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis
  • Discontinued Asthma; Chronic obstructive pulmonary disease; Hodgkin's disease; Idiopathic pulmonary fibrosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 18 May 2018 Interim efficacy, adverse events and pharmacodynamics data of phase II RIFF trial in idiopathic pulmonary fibrosis presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
  • 04 May 2018 Discontinued - Phase-II for Idiopathic pulmonary fibrosis in Mexico, Japan, Peru, Belgium, United Kingdom, Poland, Italy, France, Canada, Australia, Spain, Germany and USA (SC) (Chugai Pharmaceuticals pipeline, May 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top